Baimai ointment
Commercial- Indications
- Osteoarthritis
Company intelligence / Profile preview
Nanjing Baimai Biotechnology Co., Ltd.
Nanjing, Jiangsu Province, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Nanjing Baimai Biotechnology has developed and patented a novel crystal form of roxasistat hydrate, a small molecule HIF prolyl hydroxylase inhibitor for the treatment of renal anemia. Roxasistat is already marketed in China by another company; this entity appears to be focused on chemical synthesis and formulation innovation rather than clinical development or commercialization.[2]
- Therapeutic areas
- Nephrology
- Modalities
- Small molecules
- Industry
- Drug Discovery Services
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Nanjing Baimai Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing Baimai Biotechnology Co., Ltd..